Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Published Date: 24 Jun 2024

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

4.

Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement

5.

Kate Middleton Reaches Cancer Treatment Milestone


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot